CAS: 99489-94-8

Relaxin H2 is a hormone that is produced in the ovaries and has significant interactions with cyclase. It has been shown to bind to the receptor for relaxin and inhibit its activity. Relaxin H2 has been shown to be a potent inhibitor of cardiac growth factor-β1, which may contribute to its anti-fibrotic effects. This drug is also an inhibitor of fatty acid synthesis and can lead to metabolic disorders, such as glomerular filtration rate, by inhibiting the production of natriuretic peptide levels.

Relaxin-2 is a peptide hormone that belongs to the insulin family of hormones. It is produced by the corpus luteum and placenta. The relaxin-2 receptor is a G protein coupled receptor belonging to the superfamily of class A receptors, which are known as rhodopsin-like receptors. Relaxin-2 has been shown to activate ion channels in cells, leading to an increase in intracellular calcium levels. This hormone has also been shown to inhibit protein interactions and regulate cell growth and differentiation through its interaction with the receptor. The pharmacological effects of relaxin-2 are mediated by binding to the ligand-binding domain on the receptor, which leads to activation of a number of intracellular signaling pathways.

Relaxin H2 is the major stored and circulating isoform of the peptide hormone relaxin in humans. This pregnancy hormone has also shown cardioprotective activity. The observed long-term effects of relaxin H2 on connective tissues may be due to alterations in the turnover of collagen and proteoglycans.